

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



杭州启明醫療器械股份有限公司  
**Venus Medtech (Hangzhou) Inc.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2500)**

### **APPOINTMENT OF CHIEF FINANCIAL OFFICER**

Reference is made to the announcement of Venus Medtech (Hangzhou) Inc. (the “**Company**”) dated August 23, 2024 in relation to the third quarterly update on the resumption progress. The board of directors (the “**Board**”) of the Company is pleased to announce that Mr. Bing Zhu (“**Mr. Zhu**”) has been appointed as the chief financial officer of the Company with effect from September 9, 2024.

The biographical details of Mr. Zhu are set out below:

**Mr. Zhu Bing** (“**朱秉**”) (“**Mr. Zhu**”), aged 59, has over 30 years of experience in business and finance management, especially deep knowledge and experience in the full supply chain of the China biotech industry in recent ten years. Prior to joining the Company, Mr. Zhu served as the chief financial officer of Zhejiang Innoforce Pharmaceuticals Co., Ltd. from March 2020 to December 2022, the chief financial officer of Gmax Biopharm International Ltd. from May 2018 to February 2020 and the chief financial officer and chief operating officer of Crown Bioscience International (Taipei Exchange: 6554) from November 2013 to August 2017. Before that, he successively served as the chief strategy officer of LDK Solar Company Ltd. (NYSE: LDK), the director and chief financial officer of Chemspec International Ltd. (NYSE: CPC), and the director and chief financial officer of Canadian Solar Inc (NASDAQ: CSIQ).

Mr. Zhu received a bachelor’s degree in business administration from Zhejiang University of Technology in 1986 and a master’s degree in Business Administration from China-Europe International Business School in 1993.

The Board would like to express its warmest welcome to Mr. Zhu on his new appointment in the Company.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on November 23, 2023 and will remain suspended pending the fulfillment of the Resumption Guidance as specified by the Stock Exchange.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Venus Medtech (Hangzhou) Inc.**  
**Mr. Lim Hou-Sen (Lin Haosheng)**  
*Executive Director*

Hangzhou, September 9, 2024

*As at the date of this announcement, the executive Directors are Mr. Lim Hou-Sen (Lin Haosheng), Mr. Liqiao Ma and Ms. Meirong Liu; the non-executive Directors are Mr. Ao Zhang and Mr. Wei Wang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu and Mr. Chi Wai Suen.*